Michel Maira

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

Jeffrey A. Engelman, Liang Chen, Xiaohong Tan et al. · Nature Medicine · 2008 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

Violeta Serra, Ben Markman, Maurizio Scaltriti et al. · Cancer Research · 2008 · 796 citations · Full text

Medicine, Oncology, Pharmacology +16

Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo

Terence O’Reilly, Markus Wartmann, Joseph Brueggen et al. · Cancer Chemotherapy and Pharmacology · 2008 · 71 citations

Medicine, Oncology, Pharmacology +11

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors

Lynsey Vaughan, Paul A. Clarke, Karen Barker et al. · Oncotarget · 2016 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Characterization and targeting of phosphatidylinositol-3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in renal cell cancer

Aymen Elfiky, Saadia A. Aziz, Patricia J. Conrad et al. · Journal of Translational Medicine · 2011 · 51 citations · Full text

Medicine, Oncology, Pharmacology +17